2026 Summer Intern – Global Real World Evidence at Acadia Pharmaceuticals

Parsippany, New Jersey, United States

Apply Now

Not SpecifiedCompensation

InternshipExperience Level

InternshipJob Type

UnknownVisa

Biopharmaceutical, Pharmaceutical, HealthcareIndustries

Requirements

Working towards a PharmD or PhD degree in outcomes research, health services research, health economics, statistics, epidemiology, public health, pharmacy or a related discipline, with interest in RWE, HEOR, Medical Affairs, and the pharmaceutical industry
Has previously taken courses related to life sciences, outcomes research, statistics or related field
Demonstrated proficiency in literature review and using MS Office tools
Demonstrated excellent time management, verbal and written communication skills
For Parsippany-based roles: Expected to work no less than 4 days at the site in Parsippany, New Jersey, on days in conjunction with assigned team; may work 1 day per week remotely
Ability to complete the entire 10-week program (from May 26, 2026 to July 31, 2026) and commit to 37.5 hours per week
Cumulative 3.0 GPA or above; college transcript required (must mail official transcript by application deadline to specified address)
Currently enrolled in an accredited institution

Responsibilities

Work in one or more disease areas including Reproductive Medicine, Uro-Oncology, Microbiome, and Orthopedics to support RWE activities for pipeline and post-launch products
Support the development of literature reviews, retrospective claims database analyses, and electronic medical record (EMR) studies
Assist in conceptualizing research strategies and developing materials such as slide decks, summary reports and research abstracts
Develop summaries and documentations of the latest FDA guidelines and regulations on industry compliance related to RWE
Attend team and cross-functional meetings to acquire an understanding of how medical strategies and tactics contribute to the overarching goals within a pharmaceutical company
Work with cross-functional teams to understand how RWE is utilized to support the clinical and economic propositions of Ferring products among population health decision-makers
Develop a final presentation summarizing the accomplishments made during the internship

Skills

Real World Evidence

RWE

Literature Review

Evidence Generation

Data Analysis

Pharmaceutical Research

Cross-Functional Collaboration

Acadia Pharmaceuticals

Develops therapies for neurological disorders

About Acadia Pharmaceuticals

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these disorders while also promoting diversity, equity, and inclusion within their operations.

Dallas, TexasHeadquarters

1993Year Founded

$813.4MTotal Funding

ACQUISITIONCompany Stage

Biotechnology, HealthcareIndustries

501-1,000Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Holidays

Paid Sick Leave

Paid Parental Leave

Tuition Reimbursement

Risks

Increased competition in CNS drug market may impact Acadia's market share.

Potential clinical trial delays could affect drug approval timelines.

Dependence on partnerships poses risks if collaborations face challenges or dissolve.

Differentiation

Acadia focuses on CNS disorders with unmet medical needs, like Parkinson's and Rett syndrome.

The company has a strong R&D foundation, developing innovative small molecule drugs.

Acadia's strategic partnerships enhance its research capabilities and market reach.

Upsides

Acadia's collaboration with Saniona expands its portfolio with SAN711 for neurological disorders.

Health Canada's approval of Daybue boosts Acadia's presence in the Canadian market.

The rise of personalized medicine aligns with Acadia's targeted therapy approach.

Land your dream remote job 3x faster with AI

Try Jobo Free